DFS vs SYRE
DFS (DFS) versus Spyre Therapeutics Inc. (SYRE) — a side-by-side from cached financials, not a winner call.
DFS (DFS) common stock.
Spyre Therapeutics Inc. (SYRE) is a biotechnology company listed on NASDAQ.
DFS does not have a complete income-statement cache yet.
Latest reported SYRE revenue for 2025-12-31 was $0. Net income was -$155.2M. SYRE currently screens at market cap $7.60B.
SYRE currently screens at market cap $7.60B.
Not investment advice. Open the DFS and SYRE stock pages for the full models.
Not investment advice.